could be undertaken. Contusion size was determined with volumetric measurements in which standardized window and level settings were used to define hemorrhage and edema. For a summary of demographic and clinical details of the study cohort see Table 1 . Approval for the study was obtained from the University of Natal's Institutional Review Board.
The presence of APOE was determined using the onestage polymerase chain reaction method with Cfo1 restriction isotyping. 10, 32 Because of the varying prevalence rates of the APOE gene in most major population groups, we used an established local cohort of black Zulu-speaking female patients as controls. 4, 5 The majority (96%) of the patients in the study cohort were black Zulu-speaking males. We believed that this would have had no influence on the frequency of distribution of alleles or the generation of genotypic status, because the APOE gene is autosomal in nature and has the same genetic characteristics in either sex.
The allele frequencies for APOE gene in the patients with contusions (study group) were estimated by the gene counting method. The chi-square statistic was used to test for goodness-of-fit to the Hardy-Weinberg equilibrium, and the variance in the allele frequencies was expressed in terms of the 95% CI. The number of patients who experienced a poor outcome in each group, with and without the APOE-⑀4 allele, was compared. Logistic regression analysis was performed to control for randomization (study or control group for the ongoing clinical contusion trial), age, admission GCS score, 30 contusion volume, and type of neurosurgical management. Outcome at a minimum of 6 months of follow up was recorded and dichotomized into good (GOS Score 4 or 5) and poor (GOS Score 1-3) classifications.
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Results
In the final study cohort of 110 black Zulu-speaking patients with traumatic cerebral contusion, APOE status was determined on admission. The frequencies in the study for APOE-⑀2, -⑀3, and -⑀4 alleles were 0.23, 0.56, and 0.21, respectively. No major difference in frequency distribution of genotypes between the study and control groups was noted, except for the APOE-⑀4 allele. Homozygous E4/4 (two APOE-⑀4 alleles) in the study group occurred at a much lower frequency when compared with the control group (p = 0.06, chi-square test; Table 2 ).
Eleven (24.4%) of 45 patients in whom the APOE-⑀4 allele was present experienced a poor outcome, compared with 10 (15.4%) of 65 patients without this allele (p = 0.34, chi-square test). Both patients with homozygous APOE-⑀4 alleles experienced a good outcome (GOS Score 5), whereas 11 (25.6%) of 43 with heterozygous alleles (only one APOE-⑀4 allele) were recorded as having a poor outcome, compared with 10 (15.4%) of 65 patients with heterozygous alleles without APOE-⑀4 (p = 0.2, chi-square test). No significant relationship was recorded between presence of the APOE-⑀4 allele with regard to age (p = 0.13) and admission GCS (p = 0.26) or GOS scores (p = 0.53). In addition, no difference was recorded between the groups with regard to patients who were comatose (GCS Score Յ 8) compared with those who were not comatose on admission (p = 0.158, chi-square test) and between APOE status and outcome at a minimum of 6 months of follow up (Tables 3 and 4 risk factors when controlling for age, randomization to contusion trial, admission GCS score, contusion volume, and type of neurosurgical management (Table 5) . Finally, the risk of a poor outcome was greater in patients in whom the APOE-⑀4 allele was present (relative risk 1.59; 95% CI 0.74-3.42).
Discussion
The presence of an APOE-⑀4 allele has been shown to be associated with a poor outcome after spontaneous nonaneurysmal intracerebral hemorrhage, 1 hemorrhage associated with amyloid angiopathy, 9, 19, 21 subarachnoid hemorrhage, 23 and closed head injury. 7, [15] [16] [17] 31 More recently, an increased risk of developing cerebral amyloid angiopathy has been reported in patients recovering from TBI. 14 An increasing appreciation for the role of APOE in modifying neurological outcome after TBI has been reported recently, although the mechanisms by which this occurs remain poorly defined. The APOE-⑀4 allele is associated with reduced growth and branching of neurites in cell culture, an effect that is mediated by the low-density lipoprotein receptor-related protein, which mediates entry of APOE into neurons, and is often increased after injury. The APOE-⑀4 allele has been found to promote more rapid aggregation of amyloid ␤-protein into amyloid fibrils. 28, 29 Recent reports on transgenic closed TBI models also support the role of APOE in the inflammatory response and neuronal repair mechanisms after TBI. 3, 18 Human APOE exhibits genetically determined polymorphism with three common alleles (APOE-⑀2, -⑀3, and -⑀4), and has varying prevalence rates with regional variations in all populations examined to date. 5, 8 The frequency of APOE-⑀4, the ancestral allele, has been documented to be higher in sub-Saharan population groups (Pygmies, Khoi San [Bushmen], and Africans) 5, 8, 12, 33 and has also been confirmed in the various black ethnic groups residing in South Africa. 4, 17, 25 In contrast to other reports documenting the association between the APOE-⑀4 allele and human TBI, our study consists of a unique black cohort with homogeneous neuropathological findings, and it is the only clinical study to date that does not support the influence of the presence of the APOE-⑀4 allele on TBI outcome. In this study we recorded a nonsignificant excess frequency for the presence of the APOE-⑀4 allele in patients who experienced a poor outcome; the relative risk was 1.6 times that of patients without the APOE-⑀4 allele. This nonsignificant relationship was maintained even when multiple regression analysis was performed to control for confounding factors ( Table  5 ). The CI (0.74-3.42) for an effect of the APOE-⑀4 allele is large, and therefore neither a favorable nor an unfavorable effect of the allele can be definitely excluded. In support of our results, however, both of the patients in whom the APOE-⑀4 were homozygous and 34 (75%) of 45 with heterozygous alleles experienced a good outcome at a minimum of 6 months of follow up, which is incompatible with an APOE-⑀4 allele effect.
The study cohort had a markedly higher prevalence rate of the APOE-⑀2 and -⑀4 alleles (0.23 and 0.21, respectively) than that seen in other population groups (0-0.146 for APOE-⑀2 and 0.064-0.368 for APOE-⑀4). 4, 8 Differences in allele frequency between study and control groups were recorded for all genotypes, with a near significance in the homozygous APOE-⑀4 genotype (2% in the study group compared with 8% in the control group). There is presently no reasonable explanation for this marked difference in the frequency of the homozygous APOE-⑀4 allele between the two groups, but as mentioned earlier, we believe that this effect is not based on gender differences between the groups. Due to the small number of female patients (four) in the study cohort, no meaningful analysis of the influence of the APOE-⑀4 allele on sex and outcome could be performed. This is the first clinical report in which the relationship between the presence of APOE-⑀4 alleles and TBI has been documented in a cohort of African patients with homogeneous neuropathological findings. Furthermore, the absence of a significant effect of APOE polymorphism on homogeneous closed TBI is contrary to the general body of evidence published thus far and appears to be similar to the conflicting reports on the role of APOE in thromboembolic stroke. 2, 20 Genetic studies documenting the effect of the APOE-⑀4 allele on TBI outcome have been performed mainly in caucasian and caucasian-derived populations; however, to our knowledge no previous systematic evaluation documenting the association in African populations exists. We postulate that this difference in the APOE-⑀4 allele's variable expression and its effect on TBI outcome in caucasian and African patients may be related either to interpopulation differences in the sequence variation underlying the three protein isoforms of APOE; the presence of other modifier gene(s); and/or, more importantly, the gene-environment interactions, which may play a significant role in modifying the response to TBI in our patient population.
We recommend that in future studies researchers should try to include patients from other major racial groups to determine whether the APOE effect consistently modifies the genetic response to TBI. The recent interest in predicting outcome after TBI by using molecular and genetic markers, the potential medicolegal ramifications, and the high interpopulation and regional variation of the APOE gene, war- rants further studies. Possibly, even community-based investigations should be conducted, as well as ones in other geographical regions, to confirm these findings. 0.6 APOE-⑀4 ϩ age ϩ admission GCS score ϩ randomization 1.3 0.5-3.7 0.6 APOE-⑀4 ϩ age ϩ admission GCS score ϩ randomization ϩ contusion size 1.4 0.5-4.5 0.5 APOE-⑀4 ϩ age ϩ admission GCS score ϩ randomization ϩ contusion size ϩ type of neurosurgical management 0.9 0.3-3.6 0.9 * According to the chi-square test.
